online ISSN 2415-3176
print ISSN 1609-6371
logoExperimental and Clinical Physiology and Biochemistry
  • 9 of 11
ECPB 2017, 80(4): 57–60
Research articles

Role of Oxidative Stress Indicators in Development of Chronic Kidney Disease in Patients with Type 2 Diabetes


Abstract. Diabetes mellitus is the 4 main reason of death in the whole world. There are 382 million of people, suffering from diabetes in the world, in Ukraine 1,04 million. 90 % of all cases is type 2 diabetes. Obesity is the main risk of development of type 2 diabetes. 600 million people in the world suffer from obesity, 9 million – in Ukraine. Diabetes mellitus and obesity are the main risk factors of arterial hypertension, stroke, coronary artery disease, heart failure and chronic kidney disease. Diabetic nephropathy in most cases leads to the end stage of renal disease and recquires dialysis. Obesity in patients with comorbidities plays a huge role in disease progression. Obesity leads to chronic inflammation, what results in insulin resistance, metabolic syndrome and type 2 diabetes. Obesity with type 2 diabetes leads to hyperfiltration, albuminuria, activation of angiotensin-aldosteron system and release of proinflammatory cytokines. Incidence of type 2 diabetes is growing every year. Vascular complications of diabetes are dangerous and in the most cases lead to death. Among them chronic kidney disease takes special place. Kidney impairment in patients with type 2 diabetes is asymptomatic on the early stages, but it quickly develops to the end stage of renal disease. That’s why it is important to diagnose it on the early stages. Type 2 diabetes is related to inflammation, oxidative stress and endothelial dysfunction. But it remains unknown if these processes lead to kidney damage in such patients, what plays a key role in disease progression. Malondialdehyde is a marker of oxidative stress and its accumulation leads to endothelium damage. Oxide dismutase is an antioxidant ferment and it protects human body from toxic radicals. The aim of the study is to investigate if there is any connection between oxidative stress indicators and markers of chronic kidney disease. The investigation included 80 patients with type 2 diabetes. Except standard laboratory and physical examinations, additional blood sample has been taken for malondialdehyde and oxide dismutase detection; also nitrogen oxide and its metabolites have been measured. All patients have been divided into 2 groups: without and with chronic kidney disease. The results of the study showed that in patients with chronic kidney disease level of malondialdehyde has been significantly higher, than in patients without kidney damage. But 1 group has had a level of oxide dismutase much higher. With decrease of glomerular filtration rate level, a level of malondialdehyde also increases. This confirms a role of oxidative stress products in kidney impairment in patients with type 2 diabetes.

Added: 17.11.2017

Keywords: diabetes mellitus, chronic kidney disease, hydrogen sulfide, malondialdehyde, nitrogen oxide

Full text: PDF (Ukr) 768K

  1. 1. Gorshunska M. Oxidative stress in patients with type 2 diabetes mellitus: relation to characteristics of the development, progression and complications (Review and our own results). Endocrinol. problems. 2012;3:112–24.
  2. 2. Goryachkovskyi AM. Clinical biochemistry. Odessa.1998;(2):368–9.
  3. 3. Kiselyk IO, Lutsyk MD, Shevchenko L. Osoblyvosti vyznachennya nitrativ ta nitrytiv v peryferychniy krovi u khvorykh na virusni hepatyty ta pry syndromi zhovtyanytsi inshoyi etiolohiyi. Lab. diahnostyka. 2001;3:43–5.
  4. 4. Tymyrbulatov MA, Seleznev EY. Metod povyshenyya yntensyvnosty svobodnoradykalʹnoho okyslenyya lypydosoderzhashchykh komponentov krovy y eho dyahnostycheskoe znachenye. Lab Delo. 1981;(4):209–11.
  5. 6. Dugbartey G. Diabetic nephropathy: A potential savior with 'rotten-egg' smell. Pharmacol. Reports. 2017;69(2):331–9.
  6. 7. Gupta S, Gambhir J, Kalra O. Association of biomarkers of inflammation and oxidative stress with the risk of chronic kidney disease in Type 2 diabetes mellitus in North Indian population. J Diabetes Complications. 2013;27(6):548–52.
  7. 8. Pergola P, Krauth M, Huff J. Effect of Bardoxolone Methyl on Kidney Function in Patients with T2D and Stage 3b–4 CKD. Am J Nephrol. 2011;33:469–76.
  8. 9. Pieme C, Tatangmo J, Simo G, Biapa СР, Ama Moor V, Moukette B et al. Relationship between hyperglycemia, antioxidant capacity and some enzymatic and non- enzymatic antioxidants in African patients with type 2 diabetes. BMC Res Notes; 2017;10:1–7.
  9. 10. Sauriasari R, Andrajati R, Azizahwati, Saputri D, Muris R, Manfaatun A et al. Marker of lipid peroxidation related to diabetic nephropathy in Indonesian type 2 diabetes mellitus patients. Diabetes Res Clin Pract. 2015;108(1):93–200.
  10. 11. Xu G, Luo K, Liu H, Huang T, Fang X, Tu W et al. The progress of inflam- mation and oxidative stress in patients with chronic kidney disease. Ren Fail. 2015;37(1):45–9.

Програмування -